WASHINGTON — A new report out from AARP today provides additional insight into the impact of a historic new financial protection for our nation’s nearly 55 million Medicare drug plan enrollees. For the first time ever, beginning January 1, 2025, Medicare drug plans will limit enrollees’ annual out-of-pocket spending to $2,000, thanks to a provision in the 2022 Inflation Reduction Act that AARP championed. Specifically, the report shows that 94% of all Part D enrollees expected to reach the new cap in 2025 will have lower total (i.e., premiums and cost sharing) out-of-pocket costs, saving an average of $2,474 nationally. The report also provides state-level data and estimates that 95% of Part D enrollees who will reach the out-of-pocket cap will have lower out-of-pocket health costs in 33 states plus the District of Columbia.

According to a new AARP survey exploring the second half of life, most older adults have an optimistic outlook on life and expect their lives to improve as they get older. Nearly 9 in 10 are at least somewhat optimistic about their future, with half being extremely or very optimistic.

Today, AARP Executive Vice President and Chief Advocacy and Engagement Officer Nancy LeaMond issued the following statement in response to the Centers for Medicare & Medicaid Services (CMS) announcement of the first Medicare negotiated drug prices as part of the 2022 prescription drug law:

AARP CEO Jo Ann Jenkins issued the following statement in response to the Medicare and Social Security Trustees Reports released today:

Today, AARP CEO Jo Ann Jenkins issued the following statement in response to President Biden’s State of the Union address:

AARP Executive Vice President and Chief Advocacy and Engagement Officer Nancy LeaMond issued the following statement today following the House Budget Committee vote approving fiscal commission proposals that include Social Security and Medicare

AARP Executive Vice President and Chief Advocacy and Engagement Officer Nancy LeaMond issued the following statement in response to the Centers for Medicare & Medicaid Services proposal to require federal minimum staffing levels in nursing homes.

AARP Executive Vice President and Chief Advocacy and Engagement Officer Nancy LeaMond issued the following statement in response to the Centers for Medicare & Medicaid Services’ list of the first 10 drugs to be negotiated for lower prices by Medicare.

List prices for the 25 brand-name drugs with the highest total Medicare Part D spending in 2021 have increased by an average of 226%—or more than tripled—since they first entered the market, a new report from AARP’s Public Policy Institute shows.

AARP Executive Vice President and Chief Advocacy and Engagement Officer Nancy LeaMond issued the following statement in response to the Centers for Medicare & Medicaid Services’ final implementation guidance of the Medicare Drug Price Negotiation Program.